NFKB1 and Parkinson disease: Studies using exogenously supplied IL10 and TGFβ1 have shown potent effects at inhibiting the canonical signaling pathway of NF-κB and in reducing neurotoxicity induced by either LPS or MPTP in PD models [60, 104–106].